Strands and vitreous adhesion bands can either be dissected noninvasively, transpupillarily by photodisruptive pulses of a Nd:YAG laser, operated in the photodisruptive mode, or invasively using an Er:YAG laser and specialized fibers. The previously used CO2, Ho:YAG, and ultraviolet lasers have become less popular in the recent past. When using the transpupillary method, specialized contact lenses are required. Noninvasive methods avoid the risks incurred with invasive methods, but they require specialized knowledge, which is not available usually in vitreoretinal services. The invasive laser method provides a number of advantages typical of laser-tissue interaction. Advances in electrosurgical methods have opened the door to a new class of miniaturized electrosurgical equipment with which tissue dissection is made possible by plasma due to dielectrical breakdown which allows the pulse energy to be reduced to a very low level, resulting in a highly localized tissue effect. None of these methods has yet been considered for clinical use, mainly because the presently used mechanical methods are thought to be optimal by the majority of vitreoretinal surgeons.

Keywords:
Vitreolysis, Vitreotomy, Vitrectomy, Photodisruption, Nd:YAG laser, Er:YAG laser, Ho:YAG laser, CO2 laser
1.
Oyakawa RT, Schachat AP, Michels RG, Rice TA: Complications of vitreous surgery for diabetic retinopathy. I. Intraoperative complications. Ophthalmology 1983;90:517–521.
2.
Brown GC, Benson WE: Treatment of diabetic traction retinal detachment with the pulsed neodymium-YAG laser. Am J Ophthalmol 1985;99:258–262.
3.
Fankhauser F, Kwasniewska S, Van der Zypen E: Vitreolysis with the Q:switched laser. Arch Ophthalmol 1985;103:1166–1171.
4.
Little HL, Jack RL: Q-switched neodymium:YAG laser surgery of the vitreous. Graefe’s Arch Clin Exp Ophthalmol 1986;224:240–246.
5.
Capon MRC, Polkinghorne PJ, Hamilton AM: Nd:YAG laser photodisruption of vitreous membranes using +90-diopter lens. Laser Light Ophthalmol 1988;2:145–148.
6.
Jagger JD, Hamilton AMP, Polkinghorne PJ: Q-switched neodymium YAG laser vitreolysis in the therapy of posterior segment disease. Graefe’s Arch Clin Ophthalmol 1990;228:222–225.
7.
Hrisomalos NF, Jampol LM, Moriarty BJ: Neodymium-YAG vitreolysis in sickle cell retinopathy. Arch Ophthalmol 1987;105:1087–1091.
8.
Tassignon MJ, Brihaye M, Stempels N: Nd:YAG laser treatment in preretinal macular fibrosis. Graefe’s Arch Clin Exp Ophthalmol 1987;225:315–320.
9.
Aron-Rosa D, Greenspan DA: Neodymium:YAG vitreolysis. Int Ophthalmol Clin 1985;25:125–134.
10.
Berglin L, Stenkula S, Crawford S, Oehrström A: A new technique of treating rhegmatogenous retinal detachment using the Q-switched Nd:YAG Laser. Ophthalmic Surg 1987;18:890–892.
11.
Fleck BW, Dhillon BJ, Khanna V: Nd:YAG laser augmented pneumatic retinopexy. Ophthalmic Surg 1988;19:855–858.
12.
Rol P, Fankhauser F, Kwasniewska S: A new contact lens for posterior vitreous photodisruption. Invest Ophthalmol Vis Sci 1986;27:946–950.
13.
Peyman GA: Contact lenses for Nd:YAG applications. Retina 1984;4:129–131.
14.
Rol P, Fankhauser F, Kwasniewska S: Evaluation of contact lenses for laser therapy. Lasers Ophthalmol 1986;1:1–20.
15.
Rol P, Fankhauser F, Kwasniewska S: Aiming accuracy in ophthalmic laser microsurgery. Ophthalmic Surg 1986;17:278–282.
16.
Lörtscher HP: Laser induced breakdown for ophthalmic applications; in Trokel SL (ed): YAG Laser Ophthalmic Surg. Norwalk, Appleton Century Croft, 1983, pp 39–66.
17.
Vogel A: Optical Breakdown in Water and Ocular Media, and Its Use for Intraocular Photodisruption. Aachen, Shaker Verlag, 2001, p 192.
18.
Riquin D, Fankhauser F, Lörtscher HP: Contact glasses for use with high power lasers. Int Ophthalmol 1983;6:191–200.
19.
Dieckert AM, Mainster MA, Ho PC: Contact lenses for laser application. Ophthalmol Instrument Book 1984;91(suppl):97.
20.
Jenkins JA, White HE: Fundamentals of Optics, ed 3. Kogakusha, McGraw-Hill, 1951, p 146.
21.
Lotmar E: Theoretical eye with aspherics. J Opt Soc Am 1971;61:1522–1529.
22.
Fankhauser F, Kwasniewska S: Neodymium:yttrium-aluminium garnet laser; in L’Esperance FA Jr (ed): Ophthalmic Lasers, ed 3. St. Louis, Mosby, 1989, pp 781–886.
23.
Fankhauser F: Lasereingriffe an den vorderen Augenabschnitten und am Glaskörper; in Mackensen G, Neubauer H (eds): Augenärztliche Operationen, ed 2. Berlin, Springer, 1989, pp 281–362.
24.
Pellin MJ, Williams GA, Young CE: Endoexcimer laser intraocular ablative photodecomposition (letter). Am J Ophthalmol 1985;99:483.
25.
Lewis A, Palanker D, Hemo I: Microsurgery of the retina with a needle-guided 193-nm excimer laser. Invest Ophthalmol Vis Sci 1992;33:2377–2381.
26.
Hemo I, Palanker D, Turovets I, Lewis A, Zauberman H: Vitreoretinal surgery assisted by the 193-nm laser. Invest Ophthalmol Vis Sci 1997;38:1825–1829.
27.
Palanker D, Turovets I, Lewis A: Dynamics of ArF excimer laser-induced cavitation bubbles in gel surrounded by a liquid medium. Laser Surg Med 1997;294–300.
28.
Palanker D, Hemo I, Turovets I, Zauberman H, Fish G, Lewis A: Vitreoretinal ablation with the 193-nm excimer laser in fluid media. Invest Ophthalmol Vis Sci 1994;35:3835–3840.
29.
Meyers SM, Bonner RF, Rodrigues MM, Ballintine EJ: Phototransection of vitreal membranes with the carbon dioxide laser in rabbits. Ophthalmology 1983;90:563–568.
30.
Borirakchayavat S, Puliafito CA, Kliman GH: Holmium-YAG laser surgery on experimental vitreous membranes. Arch Ophthalmol 1991;109:1605–1609.
31.
Walsh JT Jr, Flotte TJ, Deutsch TF: Er:YAG laser ablation of tissue: Effect of pulse duration and tissue type on thermal damage. Laser Surg Med 1989;9:314–326.
32.
Brazitikos PD, D’Amico DJ, Bernal MT, Walsh AW: Erbium:YAG laser surgery of the vitreous and retina. Ophthalmology 1995;102:278–290.
33.
D’Amico DJ, Moulton RS, Theodossiadis PG, Yarborough JM: Erbium:YAG laser photothermal retinal ablation in enucleated rabbit eyes. Am J Ophthalmol 1994;117:783–790.
34.
D’Amico DJ, Blumenkranz MS, Lavin MJ, Quiro-Merado H: Multicenter clinical experience using an erbium:YAG laser for vitreoretinal surgery. Ophthalmology 1996;103:1575–1585.
35.
Margolis TI, Farnath DA, Destro M, Puliafito CA: Erbium-YAG laser surgery on experimental vitreous membranes. Arch Ophthalmol 1989;107:424–428.
36.
Lin CP, Stern D, Puliafito CA: High-speed photography of Er:YAG laser ablation in fluid: Implications for laser vitreous surgery. Invest Ophthalmol Vis Sci 1990;31:2546–2550.
37.
Palanker D, Turovets I, Lewis A: Dynamics of ArF excimer laser-induced cavitation bubbles in gel surrounded by a liquid medium. Lasers Surg Med 1997;21:294–300.
38.
Palanker D, Hemo I, Turovets I, Zauberman H, Fish G, Lewis A: Vitreoretinal ablation with the 193 m excimer laser in fluid media. Invest Ophthalmol Vis Sci 1994;35:3835–3840.
39.
D’Amico DJ, Brazitikos PD, Marcellino GR, Finn SM, Hobart JL: Initial clinical experience with an erbium:YAG laser for vitreoretinal surgery. Am J Ophthalmol 1996;121:414–425.
40.
Binder S, Stolba U, Kellner L, Krebs I: Erbium:YAG laser vitrectomy: Clinical results. Am J Ophthalmol 2000;130:82–86.
41.
Mrochen M, Petersen H, Wüllner C, Seiler T: Experimentelle Ergebnisse zur Erbium:YAG Laservitrektomie. Klin Monatsbl Augenheilk 1998;212:50–55.
42.
Petersen H, Mrochen M, Seiler T: Comparison of erbium:yttrium-aluminium-garnet laser vitrectomy and mechanical vitrectomy. Am J Ophthalmol 2000;107:1389–1392.
43.
Mrochen M, Donitzky C, Riedel P: Investigations on the vapor bubble formation during erbium:YAG laser vitrectomy. SPIE 1999;3591:171–181.
44.
Mrochen M, Vogler K: Miniature handpiece laser at 1 μm and 3 μm wavelength for medical application. Laser Optoelectr 1996;28:38–45.
45.
Mrochen M, Semchisen V, Seiler T: Mid-infrared PRK: Ablation threshold and ablation rate as a function of pulse duration. Lasers Light Ophthalmol 1997;8:77–83.
46.
Docchio F, Sacchi CA, Marshall J: Experimental investigation of optical breakdown in ocular media under single pulse irradiation with different pulse durations. Lasers Ophthalmol 1986;1:83–93.
47.
Vogel A, Schweiger R, Frieser A, Asiyo M, Birngruber R: Intraocular Nd:YAG laser surgery: Light-tissue interaction, damage range, and reduction of collateral effects. IEEE J Quant Electr 1990;QE-26:2240–2260.
48.
Zysset B, Fujimoto JG, Puliafito CA, Birngruber R, Deutsch TF: Picosecond optical breakdown: Tissue effects and reduction of collateral damage. Laser Surg Med 1989;9:183–204.
49.
Geerling G, Roider J, Schmidt-Erfurt U: Initial clinical experience with picosecond Nd:YLF laser for intraocular therapeutic applications. Br J Ophthalmol 1989;82:504–509.
50.
Lin CP, Weaver YK, Fujimoto JG, Puliafito CA: Intraocular microsurgery with a picosecond Nd:YAG laser. Laser Surg Med 1994;15:44–53.
51.
Vogel A, Busch S, Jungnickel K, Birngruber R: Mechanisms of intraocular photodisruption with picosecond and nanosecond laser pulses. Lasers Surg Med 1994;15:32–43.
52.
Vogel A, Capon MR, Asiyo-Vogel MN, Birngruber R: Intraocular photodisruption with picosecond and nanosecond laser pulses: Tissue effects in cornea, lens, and retina. Invest Ophthalmol Vis Sci 1994;35:3032–3044.
53.
Cain CP, Toth CA, DiCarlo CD: Visible lesion thresholds from near-infrared pico- and nanosecond laser pulses in the primate eye. Laser-Tissue Interaction VIII. Proc SPIE 1997;2975:133–137.
54.
Palanker D, Turovets I, Lewis A: Electrical alternative to pulsed fiber-delivered laser microsurgery. J Appl Phys 1997;81:7673–7680.
55.
Palanker DV, Miller JM, Marmor MF, Sanislo SR, Huie P, Blumenkranz MS: Pulsed electron avalanche knife (PEAK) for intraocular surgery. Invest Ophthalmol Vis Sci 2001;42:2673–2678.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.